Clinicopathological and prognostic value of long non‑coding RNA CCAT1 expression in patients with digestive system cancer

Abstract

Colon cancer associated transcript‑1 (CCAT1) is known to play an important role in numerous types of human cancer, including bladder, prostate and ovarian cancer. However, a consistent perspective has not been established in digestive system cancer (DSC). To explore the prognostic value of CCAT1 in patients with DSC, a meta‑analysis was performed. A systematic search of PubMed, Embase, Web of Science, China National Knowledge Infrastructure, Chinese Biological Medical Literature database, Cochrane Library and WanFang database was applied to select eligible articles. Pooled odds ratios (ORs) or hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to estimate the effects of CCAT1 on pathological or clinical features. A total of 1,719 patients from 12 eligible articles were enrolled in the meta‑analysis. The results revealed that elevated CCAT1 expression was significantly related to larger tumor size (OR, 1.81; 95% CI, 1.31‑2.48), poorer differentiation (OR, 0.45; 95% CI, 0.31‑0.64), earlier lymph node metastasis (OR, 3.14; 95% CI, 2.34‑4.22) and advanced TNM stage (OR, 3.08; 95% CI, 2.07‑4.59). In addition, high CCAT1 expression predicted a poorer outcome for overall survival rate (HR, 2.37; 95% CI, 2.11‑2.67) and recurrence‑free survival rate (HR, 2.16, 95% CI, 1.31‑3.57). High expression levels of CCAT1 were there‑ fore related to unfavorable clinical outcomes of patients with DSC. These results demonstrated that CCAT1 could serve as a prognostic predictor in human DSC.